Related Experiment Video
Updated: Aug 8, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
5-benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity
Caterina Carmi1, Andrea Cavazzoni, Valentina Zuliani
1Dipartimento Farmaceutico, Università degli Studi di Parma, V.le G. P. Usberti 27/A, I-43100 Parma, Italy.
Abstract:
A series of 1,5-disubstituted hydantoins, whose structure was designed to interact at the ATP-binding site of EGFR, was synthesized and evaluated for inhibition of EGFR kinase activity and antiproliferative action. Some of these compounds, characterized by a 1-phenethyl and a 5-(E)-benzylidene substituent, inhibited EGFR autophosphorylation and polyGAT phosphorylation, and also inhibited the growth and proliferation of human A431 cells, which overexpress EGFR. These compounds can therefore be regarded as examples of a new scaffold for tyrosine kinase inhibitors.
Related Concept Videos
Mitogens and the Cell Cycle
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Antiviral Nucleoside Inhibitors
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
